




PHARMACEUTICAL 2018

Rezolute Inc.
Rank 282 of 342





PHARMACEUTICAL 2018

Rezolute Inc.
Rank 282 of 342

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 243% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 203% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 134% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	4,929
Cost of Goods Sold	0
Intangible Assets	44
Liabilities, Current	1,771
Liabilities, Non-Current	330
Other Assets	331
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	47
Other Revenues	0
Property and Equipment	5,325
Research and Development	12,095
Selling, General and Administrative Expense	8,229

Output Variable	Value in 1000 USD
Assets	10,629
Liabilities	2,101
Expenses	20,324
Revenues	0
Stockholders Equity	8,528
Net Income	-20,277
Comprehensive Net Income	-20,277
Economic Capital Ratio	-88%